Skip to main content
SpringerLink
Log in

Tecfidera captures nearly half of MS market in the USA

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Notes

  1. Treatment Algorithms in Multiple Sclerosis

Reference

  • Decision Resources. U.S. Claims Data Show That Biogen Idec's Tecfidera Captured Nearly Half of Second-Line Share Among Newly Diagnosed Multiple Sclerosis Patients. Media Release : 24 Nov 2014. Available from: URL: http://www.decisionresourcesgroup.com

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Tecfidera captures nearly half of MS market in the USA. PharmacoEcon Outcomes News 717, 40 (2014). https://doi.org/10.1007/s40274-014-1765-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-014-1765-3

Search

Navigation